FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

CGMP Violations at Indias Srikem Laboratories

FDA warns Indias Srikem Laboratories about CGMP violations and data integrity issues in its manufacturing of active pharmaceutical ingredients.

Human Drugs

2 Sunscreen Guidances Published

FDA issues two guidances on GRASE determinations for OTC sunscreen products.

FDA General

Latest FDA Warning Letters

In its latest batch of Warning Letters, FDA cites NutriResearch, Pine Pharmaceuticals, Physician Therapeutics, Srikem Laboratories and Wockhardt.

Human Drugs

Contract Manufacturing Quality Agreement Guidance

FDA issues a guidance on agency thinking on quality agreements in contract manufacturing arrangements.

Human Drugs

FDA Nixes Additional Risk-based BE Testing Actions

FDA says its activities in soliciting comment on bioequivalence testing methodologies are sufficient and no additional activities are needed.

FDA General

Is Trump Looking at Pences Health Commissioner for HHS Role?

President-elect Donald Trump meets with Indiana state health commissioner Jerome Adams, presumably as a candidate for HHS secretary or another health-...

Human Drugs

Intarcia Therapeutics NDA Filed for Type Diabetes Therapy

Intarcia Therapeutics files an NDA for ITCA 650 (exenatide) for treating Type 2 diabetes.

Federal Register

Reg Review Period on Medtronics Core Valve System

Federal Register Notice: FDA determines the regulatory review period for Medtronics Core Valve System for patent extension purposes 1,194 days.

Federal Register

Reg Review Period on Pharmings Ruconest

Federal Register Notice: FDA determines the regulatory review period for Pharming Groups Ruconest for patent extension purposes 3,502 days.

Federal Register

Reg Review Determination on Celegenes Cerdelga

Federal Register Notice: FDA determines the regulatory review period for Celgenes Cerdelga (eliglustat) for patent extension purposes 3,854 days.